In a recent transaction, John E. Imhoff, a director and ten percent owner of Guided Therapeutics Inc (OTCMKTS:GTHP), a company specializing in electromedical and electrotherapeutic apparatus, has increased his stake in the company. Imhoff purchased 1,666,667 shares of common stock at an aggregate purchase price of $150,000.
The transaction took place on September 23, 2024, as part of a Securities Purchase Agreement. Along with the shares, Imhoff also acquired warrants to purchase an additional 1,666,667 shares of common stock. These warrants can be exercised immediately upon issuance and are valid for four years with an exercise price of $0.12 per share.
Following the transaction, Imhoff now owns a total of 7,075,898 shares of Guided Therapeutics Inc. The company, incorporated in Delaware and with a fiscal year-end on December 31, is known for its medical devices and has its business address in Peachtree Corners, Georgia.
Investors often keep a close eye on insider transactions as they can provide insight into how the company's leadership perceives the value and future prospects of the business. Imhoff's recent purchase could be seen as a sign of confidence in the company's direction and potential for growth.
Guided Therapeutics Inc, previously known as SpectRx Inc, has undergone a name change since its inception. The company's common stock is traded under the ticker symbol GTHP.
InvestingPro Insights
Adding context to John E. Imhoff's recent purchase of Guided Therapeutics Inc (OTCMKTS:GTHP) shares, InvestingPro data reveals that the company's market capitalization stands at a modest $10 million. This insider transaction comes at a time when the stock has experienced significant volatility, with InvestingPro Tips highlighting that GTHP "has taken a big hit over the last week" and "generally trades with high price volatility."
Despite the recent setback, GTHP has shown a "strong return over the last three months," with InvestingPro data indicating a 50.12% price total return over that period. This contrasts with the longer-term performance, as another InvestingPro Tip notes that the "price has performed poorly over the last decade."
Financially, GTHP faces challenges. The company is "not profitable over the last twelve months," according to an InvestingPro Tip, which is reflected in its negative P/E ratio of -2.76 for the last twelve months as of Q2 2024. Additionally, with revenue of just $0.04 million in the same period and a substantial revenue decline of -44.93%, the company appears to be in a precarious financial position.
For investors considering GTHP, it's worth noting that InvestingPro offers 10 additional tips for this stock, providing a more comprehensive analysis of its investment potential. These insights could be particularly valuable given the company's status as a "niche player in the electromedical and electrotherapeutic apparatus industry" and its current financial dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.